echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > New drug for multiple sclerosis! Plegridy (polyglycol interferon β-1a) intramyal injection program approved by the FDA!

    New drug for multiple sclerosis! Plegridy (polyglycol interferon β-1a) intramyal injection program approved by the FDA!

    • Last Update: 2021-02-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    February 02, 2021 // -- Biogen recently announced that the U.S. Food and Drug Administration (FDA) has approved Plegridy (polyglycolin interferon β-1a) as a new intramuscular (IM) injection pathway for the treatment of patients with multiple sclerosis (RMS).
    this new IM dosing pathway provides good efficacy and safety, has the ability to reduce recurrence and delays progression of disability, and has the potential to significantly reduce injection point response.
    in the European Union, the Plegridy intramyal injection route was approved in December 2020.
    multiple sclerosis (MM) is an autoimmune disease that affects more than 2.3 million people worldwide.
    this approval expands Yan Jian's industry-leading portfolio in multiple sclerosis treatment, including subskin (SC) injection type Plegridy, and expands treatment options for MS patients.
    Plegridy is the only polyethyl glycol interferon approved for multiple sclerosis (MS), which has the ability to delay progression and reduce recurrence of disability.
    Plegridy was first approved by the FDA in 2014 and has been shown to significantly reduce MS recurrence, disability progress and brain damage, as well as good safety and tolerance.
    , Plegridy is available in more than 60 countries around the world.
    FDA-approved Plegridy IM administration pathway is based on data assessing the bioethics and adverse reactions associated with IM administration and subdern (SC) injection administration in healthy volunteers.
    results confirmed that the two dosing programmes were biologically equivalent and that subjects who were given IM had fewer injection site reactions (14.4% vs 32.1%) than subjects who were given SC.
    the overall safety status was similar, and the rate of reactions and adverse events at the injection site was comparable between subjects of IM-after-SC and subjects of first-SC-after-IM.
    , Chief Medical Officer, maha Radhakrishnan, said, "At Yanjian, we are committed to continuous innovation to provide MS patients with more choices to meet their individual preferences and needs.
    Plegridy is a proven effective treatment for multiple sclerosis, which will provide a different method of administration for patients with multiple sclerosis, with the potential to significantly reduce injection site response.
    () Original source: Biogen Announces FDA approval of PLEGRIDY (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.